|
1
|
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity.
|
Cancer Cell
|
2006
|
1.96
|
|
2
|
Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2.
|
Proc Natl Acad Sci U S A
|
2013
|
1.24
|
|
3
|
Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.
|
Proc Natl Acad Sci U S A
|
2014
|
1.22
|
|
4
|
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas.
|
Cancer Res
|
2009
|
1.16
|
|
5
|
Altered microRNA expression profile in human pituitary GH adenomas: down-regulation of miRNA targeting HMGA1, HMGA2, and E2F1.
|
J Clin Endocrinol Metab
|
2012
|
1.15
|
|
6
|
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
|
J Exp Med
|
2013
|
1.13
|
|
7
|
Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer.
|
Mol Oncol
|
2012
|
1.07
|
|
8
|
The cAMP-HMGA1-RBP4 system: a novel biochemical pathway for modulating glucose homeostasis.
|
BMC Biol
|
2009
|
1.04
|
|
9
|
Retracted
POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.
|
J Biol Chem
|
2012
|
0.95
|
|
10
|
cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
|
PLoS One
|
2013
|
0.94
|
|
11
|
HMGA2: A pituitary tumour subtype-specific oncogene?
|
Mol Cell Endocrinol
|
2010
|
0.92
|
|
12
|
Embryonic defects and growth alteration in mice with homozygous disruption of the Patz1 gene.
|
J Cell Physiol
|
2013
|
0.90
|
|
13
|
The eighth fibronectin type III domain of protein tyrosine phosphatase receptor J influences the formation of protein complexes and cell localization.
|
J Biochem
|
2009
|
0.86
|
|
14
|
Role of PTPRJ genotype in papillary thyroid carcinoma risk.
|
Endocr Relat Cancer
|
2010
|
0.83
|
|
15
|
The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin.
|
Eur J Cancer
|
2012
|
0.81
|
|
16
|
SOM230, a new somatostatin analogue, is highly effective in the therapy of growth hormone/prolactin-secreting pituitary adenomas.
|
Clin Cancer Res
|
2007
|
0.81
|
|
17
|
HMGA1 protein is a novel target of the ATM kinase.
|
Eur J Cancer
|
2008
|
0.81
|
|
18
|
Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
|
J Clin Endocrinol Metab
|
2013
|
0.80
|
|
19
|
Impairment of the p27kip1 function enhances thyroid carcinogenesis in TRK-T1 transgenic mice.
|
Endocr Relat Cancer
|
2009
|
0.78
|
|
20
|
Retracted
Expression of a truncated Hmga1b gene induces gigantism, lipomatosis and B-cell lymphomas in mice.
|
Eur J Cancer
|
2010
|
0.78
|
|
21
|
The Mia/Cd-rap gene expression is downregulated by the high-mobility group A proteins in mouse pituitary adenomas.
|
Endocr Relat Cancer
|
2007
|
0.77
|
|
22
|
Hmga1 null mice are less susceptible to chemically induced skin carcinogenesis.
|
Eur J Cancer
|
2007
|
0.75
|
|
23
|
Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.
|
J Exp Med
|
2017
|
0.75
|
|
24
|
POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with the human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.
|
J Biol Chem
|
2017
|
0.75
|